Literature DB >> 16703413

Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging.

Justin M Drake1, Curtis L Gabriel, Michael D Henry.   

Abstract

Bioluminescence imaging (BLI) has greatly facilitated the development of animal models of cancer, allowing sensitive detection of luciferase-expressing cancer cells in living mice. Previous efforts characterizing such models have involved small numbers of animals, limiting understanding of their performance features. We employed BLI to serially image the growth and distribution of a prostate cancer cell line, 22Rv1, after intracardiac injection into scid mice (n = 85). This approach models hematogenous dissemination of cancer cells and allows inquiry of the process of metastatic colonization at various organ sites, although accurately injecting cancer cells into the left ventricle remains challenging. Therefore, to predict injection success we measured the ratio of the thoracic bioluminescence signal to the whole body bioluminescence signal (T/WB ratio) immediately following intracardiac injection. A T/WB ratio less than 0.50 predicted the development of tumors outside of the thoracic cavity while a T/WB greater than 0.50 predicted the development of tumors entirely within the thoracic cavity, suggestive of a failed injection. Progressive tumor growth was quantified using BLI. Tumors colonized multiple organ sites including bone, liver, and adrenal glands resembling the spectrum of metastases in autopsy studies of patients with prostate cancer. Tumors growing in bone exhibited mixed osteolytic and osteoblastic features, eliciting a spiculated periosteal response. With the ability to more accurately predict injection success, we can now monitor efficacy of intracardiac injections facilitating the performance of this model.

Entities:  

Mesh:

Year:  2006        PMID: 16703413     DOI: 10.1007/s10585-006-9011-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  51 in total

1.  Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models.

Authors:  Tamara Troy; Dragana Jekic-McMullen; Lidia Sambucetti; Brad Rice
Journal:  Mol Imaging       Date:  2004-01       Impact factor: 4.488

Review 2.  In vivo models of prostate cancer metastasis to bone.

Authors:  Arun S Singh; William D Figg
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Organ-specific metastases in immunodeficient mice injected with human melanoma cells: a quantitative pathological analysis.

Authors:  H R Byers; T Etoh; K W Lee; M C Mihm; S Gattoni-Celli
Journal:  Melanoma Res       Date:  1993-08       Impact factor: 3.599

5.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

6.  Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin.

Authors:  Charles J Dimitroff; Mirna Lechpammer; Denise Long-Woodward; Jeffery L Kutok
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 7.  Animal models of bone metastasis.

Authors:  Thomas J Rosol; Sarah H Tannehill-Gregg; Bruce E LeRoy; Stefanie Mandl; Christopher H Contag
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

Review 8.  Dynamic process of prostate cancer metastasis to bone.

Authors:  Kwanchanit Tantivejkul; Linda M Kalikin; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2004-03-01       Impact factor: 4.429

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Evaluation of metastatic potential in prostate carcinoma: an in vivo model.

Authors:  Adriano Angelucci; Giovanni Luca Gravina; Nadia Rucci; Claudio Festuccia; Paola Muzi; Carlo Vicentini; Anna Teti; Mauro Bologna
Journal:  Int J Oncol       Date:  2004-12       Impact factor: 5.650

View more
  48 in total

1.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

2.  ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells.

Authors:  Justin M Drake; J Matthew Barnes; Joshua M Madsen; Frederick E Domann; Christopher S Stipp; Michael D Henry
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

3.  ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells.

Authors:  Justin M Drake; Garth Strohbehn; Thomas B Bair; Jessica G Moreland; Michael D Henry
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

4.  Exogenous MC3T3 preosteoblasts migrate systemically and mitigate the adverse effects of wear particles.

Authors:  Kate Fritton; Pei-Gen Ren; Emmanuel Gibon; Allison J Rao; Ting Ma; Sandip Biswal; Sanjiv S Gambhir; Stuart B Goodman
Journal:  Tissue Eng Part A       Date:  2012-08-14       Impact factor: 3.845

5.  Animal and cellular models of hepatocellular carcinoma bone metastasis: establishment and characterisation.

Authors:  Rui Hou; Yu-Wei Wang; Hui-Fang Liang; Zhan-Guo Zhang; Zhi-Min Liu; Bin-Hao Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-28       Impact factor: 4.553

6.  Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization.

Authors:  Afshin Varzavand; Justin M Drake; Robert U Svensson; Mary E Herndon; Bo Zhou; Michael D Henry; Christopher S Stipp
Journal:  Clin Exp Metastasis       Date:  2012-12-06       Impact factor: 5.150

7.  Integrin signaling aberrations in prostate cancer.

Authors:  Hira Lal Goel; Naved Alam; Isaac N S Johnson; Lucia R Languino
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

8.  Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Authors:  Kazuki N Sugahara; Tambet Teesalu; Priya Prakash Karmali; Venkata Ramana Kotamraju; Lilach Agemy; Olivier M Girard; Douglas Hanahan; Robert F Mattrey; Erkki Ruoslahti
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis.

Authors:  M L Teoh-Fitzgerald; M P Fitzgerald; W Zhong; R W Askeland; F E Domann
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells.

Authors:  Alla Bondareva; Charlene M Downey; Fabio Ayres; Wei Liu; Steven K Boyd; Benedikt Hallgrimsson; Frank R Jirik
Journal:  PLoS One       Date:  2009-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.